This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Chinese Academy of Sciences. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Jingyun Li: Innovator in Monoclonal Antibodies
Introduction
Jingyun Li is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on the type I interferon receptor, which plays a crucial role in various diseases.
Latest Patents
Jingyun Li holds 1 patent for his invention titled "Type I interferon receptor antibody and use thereof." This patent discloses monoclonal antibodies that bind to the type I interferon alpha receptor. These antibodies are capable of inhibiting the biological activity of type I interferons, making them valuable for treating, preventing, or diagnosing diseases mediated by these interferons. The patent also includes details on immunoconjugates, bispecific molecules, and pharmaceutical compositions that incorporate these antibodies.
Career Highlights
Jingyun Li is affiliated with the Chinese Academy of Sciences, where he conducts his research and development activities. His work has garnered attention for its potential applications in therapeutic and diagnostic settings.
Collaborations
Some of his notable coworkers include Liguo Zhang and Lishan Su, who contribute to the collaborative efforts in advancing research in monoclonal antibodies.
Conclusion
Jingyun Li's innovative work in monoclonal antibodies represents a significant advancement in biotechnology. His contributions have the potential to impact the treatment and diagnosis of diseases related to type I interferons.